Novo Nordisk Highlights New Wegovy Pill Data – Novo Nordisk (NYSE:NVO)
The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether…
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction – Novo Nordisk (NYSE:NVO)
The company also said a separate analysis showed most of the weight lost with Wegovy came from body…
CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026 – Novo Nordisk
The Centers for Medicare & Medicaid Services announced that eligible Medicare beneficiaries living with obesity will gain access…
Wegovy Pill Debut ‘Fattens’ Novo Nordisk’s Profit Outlook – Novo Nordisk (NYSE:NVO)
The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the…
What’s Going On With Novo Nordisk Stock Thursday? – Novo Nordisk (NYSE:NVO)
Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study evaluated oral semaglutide in patients aged 10–17 years…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market – GoodRx Holdings (NASDAQ:GDRX), Novo Nordisk
• GoodRx Holdings shares are advancing steadily. What’s driving GDRX shares up? This move comes amid a growing…
Novo Nordisk Expands AI Push With ChatGPT Parent OpenAI – Novo Nordisk (NYSE:NVO)
AI To Accelerate Drug Discovery The collaboration will leverage advanced AI tools to analyze complex datasets, identify promising…
Novo Nordisk Wins EU Nod To Ease Wegovy Injection Delivery – Novo Nordisk (NYSE:NVO)
The decision marks a shift away from strict cold chain requirements and positions Wegovy as the first GLP-1…
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan – Novo Nordisk (NYSE:NVO)
Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an…
Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars – Hims & Hers Health (NYSE:HIMS)
Novo Nordisk Partners with Hims & Hers Novo Nordisk has decided to sell its weight-loss drug through Hims…
Roche’s Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly – Roche Holding (OTC:RHHBY)
Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493…